Jazz Pharmaceuticals plc - SHS USD (JAZZ)

Historical Holders from Q1 2014 to Q1 2025

Symbol
JAZZ on Nasdaq
CUSIP
G50871105
Type / Class
Equity / SHS USD
All holders as of December 31, 2024
Q4 2024
Shares, excl. options
59M
Holdings value
$7.26B
% of all portfolios
0.012%
Grand Portfolio weight change
+0%
Number of holders
498
Number of buys
234
Number of sells
-222
Average Value change %
+0%
Average buys %
+0.004%
Average sells %
-0.003%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Institutional Holders of Jazz Pharmaceuticals plc - SHS USD (JAZZ)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q1 848K $105M +$11.7M $124.15 58
2024 Q4 59M $7.26B +$147M $123.15 498
2024 Q3 57.6M $6.41B +$57.4M $111.41 468
2024 Q2 57.4M $6.13B -$45.7M $106.73 447
2024 Q1 57.7M $6.95B +$71.7M $120.42 475
2023 Q4 55.2M $6.78B -$70.2M $123.00 480
2023 Q3 55.4M $7.17B -$19.7M $129.44 473
2023 Q2 55.6M $6.9B -$97.9M $123.97 458
2023 Q1 55.6M $8.13B -$92.8K $146.33 454
2022 Q4 55.9M $8.91B -$101M $159.31 467
2022 Q3 56.6M $7.55B -$94.4M $133.29 432
2022 Q2 57.1M $8.9B +$138M $156.01 441
2022 Q1 56.4M $8.78B -$114M $155.67 427
2021 Q4 57.4M $7.32B +$28M $127.40 418
2021 Q3 56.4M $7.34B -$103M $130.21 423
2021 Q2 57.1M $10.1B +$765M $177.64 481
2021 Q1 53M $8.7B +$71.3M $164.37 430
2020 Q4 52.4M $8.64B -$303M $165.05 420
2020 Q3 54.3M $7.73B +$386M $142.59 373
2020 Q2 52.1M $5.74B +$276M $110.34 371
2020 Q1 49.3M $4.92B -$262M $99.74 389
2019 Q4 51.8M $7.73B +$163M $149.28 432
2019 Q3 48.8M $6.25B +$107M $128.14 393
2019 Q2 49.1M $6.99B +$348M $142.56 400
2019 Q1 51.4M $7.34B -$214M $142.95 410
2018 Q4 52.9M $6.55B -$430M $123.96 404
2018 Q3 55.1M $9.26B -$152M $168.13 391
2018 Q2 56M $9.64B +$535M $172.30 365
2018 Q1 53.7M $8.09B -$76.3M $150.99 316
2017 Q4 54.9M $7.3B -$62.5M $134.65 317
2017 Q3 54.6M $8B +$210M $146.25 298
2017 Q2 53.1M $8.26B +$374M $155.50 311
2017 Q1 51.9M $7.53B +$546M $145.13 299
2016 Q4 51.1M $5.57B -$173M $109.03 284
2016 Q3 52.2M $6.34B -$32.4M $121.48 315
2016 Q2 53.9M $7.61B -$46.2M $141.31 353
2016 Q1 54.3M $7.09B -$237M $130.55 328
2015 Q4 56.3M $7.91B -$15.9M $140.56 338
2015 Q3 55.2M $7.33B +$37.4M $132.81 348
2015 Q2 55.6M $9.8B +$598M $176.07 364
2015 Q1 50.9M $8.79B -$334M $172.79 350
2014 Q4 54.3M $8.89B +$176M $163.73 351
2014 Q3 53.1M $8.52B +$372M $160.56 323
2014 Q2 50.5M $7.42B +$48.4M $147.01 304
2014 Q1 50.5M $7B +$311M $138.68 309